Accéder au contenu
MilliporeSigma

Rat N-ERC/mesothelin as a marker for in vivo screening of drugs against pancreas cancer.

PloS one (2014-10-28)
Katsumi Fukamachi, Masaaki Iigo, Yoshiaki Hagiwara, Koji Shibata, Mitsuru Futakuchi, David B Alexander, Okio Hino, Masumi Suzui, Hiroyuki Tsuda
RÉSUMÉ

Pancreatic ductal adenocarcinoma (PDA) is a highly lethal disease, which is usually diagnosed in an advanced stage. We have established transgenic rats carrying a mutated K-ras gene controlled by Cre/loxP activation. The animals develop PDA which is histopathologically similar to that in humans. Previously, we reported that serum levels of N-ERC/mesothelin were significantly higher in rats bearing PDA than in controls. In the present study, to determine whether serum levels of N-ERC/mesothelin correlated with tumor size, we measured N-ERC/mesothelin levels in rats bearing PDA. Increased serum levels of N-ERC/mesothelin correlated with increased tumor size. This result indicates an interrelationship between the serum level of N-ERC/mesothelin and tumor size. We next investigated the effect of chemotherapy on serum N-ERC/mesothelin levels. Rat pancreatic cancer cells were implanted subcutaneously into the flank of NOD-SCID mice. In the mice treated with 200 mg/kg gemcitabine, tumor weight and the serum level of N-ERC/mesothelin were significantly decreased compared to controls. These results suggest that serum N-ERC/mesothelin measurements might be useful for monitoring response to therapy.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Gemcitabine hydrochloride, ≥98% (HPLC)
Le tarif et la disponibilité ne sont pas disponibles actuellement.
USP
Gemcitabine hydrochloride, United States Pharmacopeia (USP) Reference Standard
Le tarif et la disponibilité ne sont pas disponibles actuellement.
Gemcitabine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Le tarif et la disponibilité ne sont pas disponibles actuellement.